Skip to main content
. 2022 Jun 6;27(8):646–654. doi: 10.1093/oncolo/oyac089

Figure 4.

Figure 4.

(A) Kaplan-Meier analysis of progression-free survival comparing ECOG0/1 vs. ECOG2/3 status across all patients. (B) Kaplan-Meier analysis of progression-free survival comparing patients with prior endocrine therapy. P = .003 by log-rank. (C) Kaplan-Meier analysis of progression-free survival comparing patients with prior chemotherapy. P = .036 by log-rank.